SCHEMBL22388945

SCHEMBL22388945

COC(C)(C)CCOC(C)(C)CC(=O)Cl

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20356251 0.82 ALDH1A1 (0.31) ALDH1A1TSHRTDP1
SCHEMBL13542802 0.82 HMGCR (0.38) ALDH1A1TSHRTDP1
SCHEMBL23844667 0.81 ALDH1A1 (0.30) ALDH1A1TSHRTDP1
SCHEMBL18814190 0.81 ALDH1A1 (0.30) ALDH1A1TSHRTDP1
SCHEMBL24983621 0.80 TSHR (0.37) ALDH1A1TSHRTDP1
SCHEMBL22791713 0.79
SCHEMBL24731740 0.78 ALDH1A1 (0.31) ALDH1A1TSHRTDP1
SCHEMBL24208216 0.78 ALDH1A1 (0.31) ALDH1A1TDP1
SCHEMBL21935476 0.78 DGAT1 (0.31)
SCHEMBL22350895 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-08-03 US disclosed
US-20230057350-A1 A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-02-23 US disclosed
US-20230025327-A1 CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-01-26 US disclosed
US-20200276261-A1 A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230057350-A1 A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS BTN3A1, ANTXR2, CLTA ALDH1A1 4011/4885TSHR 863/4885TDP1 3065/4885
US-20200276261-A1 A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS TEKT1, TEK, BTN3A1 ALDH1A1 4604/4885TSHR 1321/4885TDP1 3177/4885
US-20230025327-A1 CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING TEK, TEKT1, EPCAM ALDH1A1 3961/4885TSHR 1675/4885TDP1 2182/4885
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS CD4, DCLRE1A, TOP1 ALDH1A1 3405/4885TSHR 687/4885TDP1 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.